Skip to main content

7 Results for “structural heart intervention”

FDA Approves GORE® CARDIOFORM Septal Occluder for PFO Closure to Prevent Recurrent Ischemic Stroke

Gore REDUCE Clinical Study demonstrated 77 percent relative reduction in recurrent ischemic stroke when PFO closure was combined with antiplatelet therapy, compared to antiplatelet therapy alone

Gore Completes Patient Enrollment in U.S. Pivotal Clinical Study of GORE® CARDIOFORM ASD Occluder

New addition to GORE® CARDIOFORM Occluder family is designed to treat larger atrial septal defects by adapting to the patient’s anatomy for a permanent and safe closure

Gore Receives CE Mark for the GORE® CARDIOFORM ASD Occluder for the Treatment of Atrial Septal Defects in Europe

CE Mark supported by data from the Gore ASSURED Clinical Study, demonstrating 100 percent closure success

First Patients Enrolled in the Gore RELINE MAX Clinical Study

108 patient trial to add evidence for treatment of in-stent restenosis using the GORE® VIABAHN® Endoprosthesis